Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA Jr, Chan DC, Pallansch P, Eckhardt SG. Witta SE, et al. Among authors: basche m. Clin Cancer Res. 2004 Nov 1;10(21):7229-37. doi: 10.1158/1078-0432.CCR-03-0181. Clin Cancer Res. 2004. PMID: 15534096 Clinical Trial.
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Chow LQ, Eckhardt SG, O'Bryant CL, Schultz MK, Morrow M, Grolnic S, Basche M, Gore L. Chow LQ, et al. Among authors: basche m. Cancer Chemother Pharmacol. 2008 Sep;62(4):631-46. doi: 10.1007/s00280-007-0646-x. Epub 2007 Dec 6. Cancer Chemother Pharmacol. 2008. PMID: 18058098 Free PMC article. Clinical Trial.
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
Chow LQ, Gustafson DL, O'Bryant CL, Gore L, Basche M, Holden SN, Morrow MC, Grolnic S, Creese BR, Roberts KL, Davis K, Addison R, Eckhardt SG. Chow LQ, et al. Among authors: basche m. Cancer Chemother Pharmacol. 2008 Dec;63(1):65-74. doi: 10.1007/s00280-008-0712-z. Epub 2008 Mar 5. Cancer Chemother Pharmacol. 2008. PMID: 18320191 Free PMC article. Clinical Trial.
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Kobayashi H, Eckhardt SG, Lockridge JA, Rothenberg ML, Sandler AB, O'Bryant CL, Cooper W, Holden SN, Aitchison RD, Usman N, Wolin M, Basche ML. Kobayashi H, et al. Among authors: basche ml. Cancer Chemother Pharmacol. 2005 Oct;56(4):329-36. doi: 10.1007/s00280-004-0968-x. Epub 2005 May 20. Cancer Chemother Pharmacol. 2005. PMID: 15906031 Clinical Trial.
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Green LJ, Marder P, Ray C, Cook CA, Jaken S, Musib LC, Herbst RS, Carducci M, Britten CD, Basche M, Eckhardt SG, Thornton D. Green LJ, et al. Among authors: basche m. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3408-15. doi: 10.1158/1078-0432.CCR-05-2231. Clin Cancer Res. 2006. PMID: 16740765
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD. Jameson GS, et al. Among authors: basche m. Clin Cancer Res. 2013 Jan 1;19(1):268-78. doi: 10.1158/1078-0432.CCR-12-1201. Epub 2012 Nov 7. Clin Cancer Res. 2013. PMID: 23136196 Free PMC article. Clinical Trial.
28 results